Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward V Loftus

Showing results (371-380 of 471) with videos related to

Pageof 48
Sort By:
Journal of Crohn'S & Colitis|May 31, 2018
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's DiseaseStefan Schreiber, Corey A Siegel, Keith A Friedenberg, et al.
The American Journal of Gastroenterology|August 13, 2021
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel DiseaseAdam S Cheifetz, Maria T Abreu, Waqqas Afif, et al.
Inflammatory Bowel Diseases|August 19, 2006
Microscopic colitis is not associated with cholecystectomy or appendectomyAran W Laing, Darrell S Pardi, Edward V Loftus, et al.
Inflammatory Bowel Diseases|October 16, 2019
Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel DiseaseManuel B Braga Neto, Martin H Gregory, Guilherme P Ramos, et al.
Alimentary Pharmacology & Therapeutics|September 18, 2023
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTEStefan Schreiber, Gerhard Rogler, Mamoru Watanabe, et al.
Crohn'S & Colitis 360|March 30, 2026
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY studyVipul Jairath, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|November 5, 2025
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's DiseaseMarla C Dubinsky, Geert D'Haens, Olivier Dewit, et al.
Alimentary Pharmacology & Therapeutics|April 23, 2020
Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medicationsGursimran S Kochhar, Aakash Desai, Aslam Syed, et al.
Inflammatory Bowel Diseases|April 19, 2018
Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's DiseaseParakkal Deepak, Joel G Fletcher, Jeff L Fidler, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 4, 2025
Comparative efficacy of immunomodulators, biologics, and advanced therapies for steroid-refractory acute severe ulcerative colitis: A network meta-analysis and time-to-event analysisMohammad Al Hayek, Mohammed S Beshr, Mohamedhen Vall Nounou, et al.
Pageof 48

Showing results (371-380 of 471) with videos related to

Sort By:
Pageof 48
Journal of Crohn'S & Colitis|May 31, 2018
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's DiseaseStefan Schreiber, Corey A Siegel, Keith A Friedenberg, et al.
The American Journal of Gastroenterology|August 13, 2021
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel DiseaseAdam S Cheifetz, Maria T Abreu, Waqqas Afif, et al.
Inflammatory Bowel Diseases|August 19, 2006
Microscopic colitis is not associated with cholecystectomy or appendectomyAran W Laing, Darrell S Pardi, Edward V Loftus, et al.
Inflammatory Bowel Diseases|October 16, 2019
Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel DiseaseManuel B Braga Neto, Martin H Gregory, Guilherme P Ramos, et al.
Alimentary Pharmacology & Therapeutics|September 18, 2023
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTEStefan Schreiber, Gerhard Rogler, Mamoru Watanabe, et al.
Crohn'S & Colitis 360|March 30, 2026
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY studyVipul Jairath, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|November 5, 2025
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's DiseaseMarla C Dubinsky, Geert D'Haens, Olivier Dewit, et al.
Alimentary Pharmacology & Therapeutics|April 23, 2020
Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medicationsGursimran S Kochhar, Aakash Desai, Aslam Syed, et al.
Inflammatory Bowel Diseases|April 19, 2018
Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's DiseaseParakkal Deepak, Joel G Fletcher, Jeff L Fidler, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 4, 2025
Comparative efficacy of immunomodulators, biologics, and advanced therapies for steroid-refractory acute severe ulcerative colitis: A network meta-analysis and time-to-event analysisMohammad Al Hayek, Mohammed S Beshr, Mohamedhen Vall Nounou, et al.
Pageof 48